View Older Stories View More Recent Stories
-
JPMorgan Upgrades Replimune Group (REPL) to Neutral
-
Replimune (REPL) call put ratio 1.2 calls to 1 put as share price up 105%
-
Leerink Partners Upgrades Replimune Group (REPL) to Outperform
-
Increasing unusual put option volume: REPL LBRT ARCT CRML BYND ABAT BITF EXEL
-
Wedbush Upgrades Replimune Group (REPL) to Outperform
-
FDA accepts Replimune BLA resubmission for RP1 melanoma treatment
-
H.C. Wainwright Reiterates Neutral Rating on Replimune Group (REPL)
-
JPMorgan Downgrades Replimune Group (REPL) to Underweight
-
Replimune meets with FDA on melanoma treatment application
-
H.C. Wainwright Reiterates Neutral Rating on Replimune Group (REPL)
-
Replimune schedules FDA meeting on melanoma treatment application
-
Replimune Group (REPL) PT Lowered to $8 at Jefferies
-
Important Notice to Long-term Shareholders of Replimune Group, Inc. (REPL): Grabar Law Office Investigates Claims on Your Behalf
-
Increasing unusual option volume: SMCY REPL ROIV PARA CRDF OPEN CWH PAGP LC CP
-
Cantor Fitzgerald Upgrades Replimune Group (REPL) to Overweight
-
Increasing unusual option volume: REPL CP PGEN CRDF LC INDA NEO TTI JBS HOG TER
-
Replimune (REPL) Faces Securities Class Action Following Stock's Collapse Amid FDA's Rejection of Melanoma Drug - Hagens Berman
-
H.C. Wainwright Downgrades Replimune Group (REPL) to Neutral
-
Increasing unusual put option volume: OPEN REPL NOK AAOI GRPO ATYR HPP ETHE
-
BMO Capital Downgrades Replimune Group (REPL) to Underperform
-
Barclays Downgrades Replimune Group (REPL) to Equalweight
-
Leerink Partners Downgrades Replimune Group (REPL) to Market Perform
-
Leerink Partners Reiterates Outperform Rating on Replimune Group (REPL), PT $21, 'Estimates Under Review'
-
Replimune Group (REPL) PT Lowered to $6 at Jefferies, Buy rating kept, 'see the reasonable case as accelerated approval based on interim results'
-
Increasing unusual option volume: REPL OPEN PGEN NXDR UPXI UGL AAOI
-
Wedbush Downgrades Replimune Group (REPL) to Neutral
-
Replimune Group Stock Drops More Than 75% on News of FDA Complete Response Letter - Kehoe Law Firm, P.C. Investigating Securities Claims on Behalf of Investors - REPL
-
Cantor Fitzgerald Downgrades Replimune Group (REPL) to Neutral, Only Firm Thus Far Not Buy/Overweight Rated
-
BMO Capital Reiterates Outperform Rating on Replimune Group (REPL), PT $27, 'we see a long road ahead'
-
Mizuho Desk Comments on Replimune (REPL)
-
Barclays Reiterates Overweight Rating on Replimune Group (REPL), PT $17, 'We see this as a clear positive for Iovance's Amtagvi'
-
Replimune receives FDA rejection letter for melanoma treatment
-
Replimune (REPL) 11,800 contracts of July 12.50 calls trade, share price up 6.4%
-
Increasing unusual call option volume: BTBT ACLS CNC SHLS REPL
-
H.C. Wainwright Reiterates Buy Rating on Replimune Group (REPL)
-
Cantor Fitzgerald Reiterates Overweight Rating on Replimune Group (REPL)
-
Cantor Fitzgerald Starts Replimune Group (REPL) at Overweight
-
JPMorgan Reiterates Overweight Rating on Replimune Group (REPL)
-
Replimune Group (REPL) PT Raised at Piper Sandler; 'Raising Numbers After Multiple Recent Updates'
-
Replimune Group, Inc. (REPL) Misses Q4 EPS by 235c
-
Replimune Group (REPL) PT Raised to $22 at H.C. Wainwright
-
Replimune Group (REPL) PT Raised to $27 at BMO Capital
-
Barclays Reiterates Overweight Rating on Replimune Group (REPL)
-
Replimune (REPL) Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma
-
Replimune Group (REPL) PT Raised to $19 at Jefferies
-
Replimune (REPL) Prices Upsized 6.92M Share Offering at $13/sh
-
Replimune (REPL) Announces $125M Proposed Public Offering
-
Replimune Group (REPL) PT Raised to $18 at BMO Capital
-
After-hours movers: Intuit, NetApp, Ross Stores, GAP
-
Replimune (REPL) Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway
